Mads Daugaard
Overview
Explore the profile of Mads Daugaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kang N, Xue H, Wong N, Lin Y, Classen A, Wu R, et al.
Mol Cancer Res
. 2025 Jan;
PMID: 39776163
Prostate cancer (PCa) is mainly managed with androgen deprivation therapy (ADT), but this often leads to a dormant state and subsequent relapse as lethal castration-resistant prostate cancer (CRPC). Using our...
2.
Khazamipour N, Oo H, Al-Nakouzi N, Marzban M, Khazamipour N, Roberts M, et al.
EMBO Mol Med
. 2024 Oct;
16(11):2775-2794.
PMID: 39406935
Glycosaminoglycans are often deprioritized as targets for synthetic immunotherapy due to the complexity of glyco-epitopes and limited options for obtaining specific subtype binding. Solid tumors express proteoglycans that are modified...
3.
Unal B, Kuzu O, Jin Y, Osorio D, Kildal W, Pradhan M, et al.
Nat Commun
. 2024 Oct;
15(1):8895.
PMID: 39406723
Unfolded protein response (UPR) is a central stress response pathway that is hijacked by tumor cells for their survival. Here, we find that IRE1α signaling, one of the canonical UPR...
4.
Wang Y, Scurll J, Rascon I, Cui C, Ni Y, Shi A, et al.
Epigenomics
. 2024 Sep;
16(17):1129-1132.
PMID: 39225130
Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer (PCa), emerging from advanced treatments and characterized by loss of androgen receptor (AR) signaling and neuroendocrine features,...
5.
Vidal-Calvo E, Martin-Salazar A, Choudhary S, Dagil R, Raghavan S, Duvnjak L, et al.
Nat Commun
. 2024 Aug;
15(1):7553.
PMID: 39215044
Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express is oncofetal chondroitin...
6.
Rohde M, Daugaard M, Jensen M, Helin K, Nylandsted J, Jaattela M
Genes Dev
. 2024 Aug;
38(13-14):692.
PMID: 39164094
No abstract available.
7.
Farivar N, Khazamipour N, Roberts M, Nelepcu I, Marzban M, Moeen A, et al.
Small
. 2024 Mar;
20(32):e2309495.
PMID: 38511548
Photothermal therapy (PTT) refers to the use of plasmonic nanoparticles to convert electromagnetic radiation in the near infrared region to heat and kill tumor cells. Continuous wave lasers have been...
8.
Pihl J, Clausen T, Zhou J, Krishnan N, Orum-Madsen M, Gustavsson T, et al.
ACS Nano
. 2023 Jul;
17(14):13500-13509.
PMID: 37435892
Malaria infected erythrocytes utilize the parasite protein VAR2CSA to bind to a unique presentation of chondroitin sulfate (CS) for their placenta specific tropism. Interestingly, many cancers express a similar form...
9.
Ramos L, Truong S, Zhai B, Joshi J, Ghaidi F, Lizardo M, et al.
Clin Cancer Res
. 2023 Jun;
29(17):3541-3553.
PMID: 37279093
Purpose: Histone deacetylase (HDAC) inhibition has been shown to induce pharmacologic "BRCAness" in cancer cells with proficient DNA repair activity. This provides a rationale for exploring combination treatments with HDAC...
10.
Tortora D, Roberts M, Kumar G, Kotapalli S, Ritch E, Scurll J, et al.
iScience
. 2023 May;
26(5):106525.
PMID: 37250326
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor central in the regulation of key cellular processes including cell metabolism, tissue differentiation, and regulation of the immune system. PPARγ is...